PERCUTANEOUS WOUND BARRIER
20230113181 · 2023-04-13
Assignee
Inventors
Cpc classification
A61B2017/00654
HUMAN NECESSITIES
A61M2025/0293
HUMAN NECESSITIES
A61B17/0057
HUMAN NECESSITIES
A61M29/00
HUMAN NECESSITIES
International classification
Abstract
A surface-modified cannula includes a hollow shaft having a proximal opening and one or more surface features along a portion of the length of the hollow shaft, the one or more surface features including one or more channels, one or more depressions, and/or two or more ports each extending at least partially between an outer diameter and an inner diameter of the hollow shaft. The one or more surface features are configured to enable, upon delivery of the cannula to a position proximate to a wound site in the blood vessel, collection of the patient’s blood from the wound site, and ejection of the blood along an access path to the wound site, thereby enabling blood to migrate from the wound site to a region surrounding and extending from the wound site along the access path.
Claims
1-20. (canceled)
21. A method for forming a failsafe percutaneous wound barrier at a wound site in a blood vessel, the method comprising: providing a surface-modified cannula, comprising a hollow shaft comprising an inner diameter, an outer diameter, and a proximal opening, and one or more surface features along a length of the hollow shaft, the one or more surface features comprising at least one channel, one or more depressions, and/or one or more ports, each channel, depression, or port extending at least partially between the outer diameter and the inner diameter of the hollow shaft; advancing the surface-modified cannula along an access path through skin of a patient to a position proximate or in the wound site in the blood vessel; and prior to introducing additional medical equipment via the cannula, maintaining the position of the surface-modified cannula within the access path a) for a period of time of at least ten seconds, or b) until viewing physical evidence of blood present in the tissue tract, thereby enabling the one or more surface features to collect blood of the patient from proximate a distal end of the cannula, direct the blood of the patient away from the blood vessel, and eject the blood along the access path, such that the blood migrates from the wound site to a region surrounding and extending from the wound site including along the access path.
22. The method of claim 21, wherein the hollow shaft is composed of flexible material.
23. The method of claim 21, wherein the surface-modified cannula is configured for passage of a guidewire or other medical device.
24. The method of claim 21, wherein the surface-modified cannula is a dilator or a sheath.
25. The method of claim 21, wherein the surface-modified cannula is a needle.
26. The method of claim 21, wherein the at least one channel of the surface-modified cannula follows a curved or angular path along the hollow shaft.
27. The method of claim 21, wherein the at least one channel of the surface-modified cannula comprises at least two channels disposed along a length of the hollow shaft.
28. The method of claim 21, wherein the plurality of ports of the surface-modified cannula comprises at least one distally positioned port proximate the distal opening, and at least one proximally positioned port spaced along a length of the hollow shaft from the distally positioned port to a position such that, upon delivery of the distal opening of the surface-modified cannula to the position in the wound site in the blood vessel, the proximally positioned port is disposed beneath the surface of the skin of the patient.
29. The method of claim 28, wherein the plurality of ports of the surface-modified cannula comprises at least three ports including the at least one distally positioned port, the at least one proximally positioned port, and one or more intermediate positioned ports, each of the one or more intermediate positioned ports being disposed between the at least one proximally positioned port and the at least one distally positioned port along the length of the hollow shaft.
30. The method of claim 21, wherein the plurality of ports of the surface-modified cannula are rounded in shape.
31. The method of claim 21, wherein the one or more surface features of the surface-modified cannula extend along a length of the hollow shaft of at least 20 mm.
32. The method of claim 21, wherein at least one surface feature of the one or more surface features of the surface-modified cannula is configured to enable, upon delivery of the distal end of the surface-modified cannula to the position in the wound site in the blood vessel, direction of a portion of the blood to exterior to the surface of the skin of the patient.
33. The method of claim 21, wherein the advancing and the maintaining are steps of a modified version of the Seldinger procedure.
34. The method of claim 21, further comprising: after performing the medical procedure, removing the cannula and/or the additional medical equipment from the access path, thereby exposing a core pin channel impression in the form of a portion of the surface-modified cannula via an opening in the skin of the patient, wherein the core pin channel impression provides a channel for directing any bleeding out to the skin of the patient, thereby providing a failsafe mechanism to avoid internal bleeding.
35. The method of claim 34, further comprising performing post-procedure wound management with the core pin channel.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0015]
[0016]
[0017]
[0018]
[0019]
[0020]
[0021]
[0022]
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0023] One aspect of the approaches described herein includes using familiar elements of a percutaneous medical procedure for new functions. These functions may also be described in the context of method steps, systems or system components, apparatus, or any combination thereof for creating a percutaneous wound barrier.
[0024] When referring to bleeding “complications” or “complication” and the like the general intent, unless expressly stated otherwise, is to refer to blood causing unacceptable blood accumulation and/or transfer beneath the skin such as in pseudoaneurysms, hematomas, retroperitoneal bleeding, and the like.
[0025] When referring to a “vessel” and absent any stipulation to the contrary, this generally refers to the vessel subject of the arteriotomy for vascular access.
[0026] The teachings herein depart from a conventional way of looking at its elements. For example, the subcutaneous area including interstitial loose connective tissue, blood vessels, cutaneous tissue, muscle, and like anatomical features in the access site area may be referred to as a “mold” or the like with an introducer sheath or like instrument, when present, representing what may be referred to as a “core pin” extending into the mold. Clotting material, such as blood, injected to fill the mold subsequently solidifies to become what may be referred to as a mold “casting.” The casting need not be removed from the mold, and typically both the casting and parts of the mold, like the tissue tract, would be reabsorbed or the like by the patient’s body over time. Concerning vessel wound management in general, the teachings herein are largely unconcerned with directly the vessel’s wound puncture or its closure and are more concerned with the surrounding anatomical space and any inserted instruments. The preferred intent here is to form a failsafe barrier substantially encasing the entire wound area and vessel to preventing bleeding from a failed wound closure, generally accomplished by preferably filling and clotting within internal anatomical spaces and fluid pathways that could otherwise give rise to bleeding complications when a wound closure fails. Users wanting to provide the patient such a failsafe barrier may also find benefits in a subsequently applied wound closure’s performance including cost savings, improved ease of use, improved success rate, ability to use with larger French size instruments and vessel holes, or the like. As such, one embodiment also specifically includes providing a failsafe barrier to internal bleeding pathways and enhanced performance of a wound closure approach used.
[0027] The clotting or clottable agent may be anything that converts from a material that can flow, into a material that is substantially stationary with liquids, gels, beads, and powders including four such examples. In the case of using blood, the clotted blood can also be considered to form a blood “tissue” when clotted. In such case, the methods described herein can also be thought of as changing the patient’s anatomy that is subject to a subsequent wound closure.
[0028] Performance enhancements that may be used with some embodiments for initiating or accelerating clot formation, reducing lysis of formed clot, providing pain reduction, providing clotting agent radiopacity to observe placement, and the like are discussed in the reference documents and other publications. Likewise, the choice of clotting agents, sequence of deploying a clotting agent or agents, timing of deploying a clotting agent or agents, options for apparatus, methods, and systems employed to practice the methods can all be selected from the reference documents and other publications.
[0029] A preferred embodiment begins with apparatus illustrated in
[0030] Further to
[0031] Some specialized tools may be useful in carrying out the percutaneous wound closure in different ways, for example, injecting blood with syringe 2 versus ejecting blood from vessel 4 to deploy a failsafe barrier typically as described herein and in reference documents. Pulsatile indicators like those described in reference documents and elsewhere may optionally instead be used to indicate and therefore allow controlled adjustment of clotting agent pressure developing in the patient’s wound site mold cavity when ensuring adequate placement to form a failsafe barrier. Radiopacity may be added to a clotting agent to enhance visualization of how well a clotting agent is deployed. Sheaths or a similar instrument, already know in the art to serve multiple useful purposes, can now also be used as a failsafe barrier mold core pin.
[0032] In some embodiments, a cannula, guidewire, needle, sheath and/or dilator used for percutaneous wound access is ported, grooved, or otherwise includes surface features modified for the purposes of procoagulation and/or vessel blood pressure pulse communication for vessel wall location (as referred to herein, a “surface-modified cannula” or “cannula”). The surface features, in some implementations, are designed to collect blood from the vessel and eject or deposit the blood along an access path to the wound site to deploy a failsafe barrier. The cannula, sheath, and/or dilator, in some examples, may range from 2 French to 30 French depending upon the style of the device (e.g., cannula, needle, guidewire, sheath, dilator, etc.). The cannula, guidewire, needle, sheath, and/or dilator, in some examples, may be formed of polymers and/or surgical grade metals.
[0033] Such a surface-modified cannula, sheath, guidewire, needle, and/or dilator, in some implementations, may be used with additional apparatus. For example, the surface-modified cannula, sheath, guidewire, needle, and/or dilator may support blood transfer and accumulation into another container, such as a syringe or a pulsatile indicator. In another example, the surface-modified cannula, sheath, guidewire, needle, and/or dilator may support the transfer of blood to or through additional clot activation apparatus or material, such as various apparatus and materials described in U.S. Pat. No. 6,159,232 to Nowakowski, incorporated by reference herein in its entirety. The materials, in some examples, may include a porous matrix such as, in some examples, glass fiber or beads, celite, kaolin, fibrin, cotton, and blood incompatible polymers or metals. In another example, the surface-modified cannula, sheath, guidewire, needle, and/or dilator may support the transfer of blood to or through additional anticoagulant neutralizing apparatus and/or agents (e.g., anticoagulant inhibitor, procoagulant, etc.), such as, in some examples, thrombin, polymers of selective electrical charge or diethylaminoethyl cellulose in catalytic form, or protamine sulfate.
[0034] In some implementations, a surface-modified cannula includes one or more surface features that are at least partially filled or obstructed with a clot activation material such that the blood is ejected after passing through the clot activation material. The clot activation material, for example, may be a procoagulant or a porous matrix. In some embodiments, obstructing the one or more surface features involves at least partially filling or obstructing the surface feature(s) with a clot activation material by inserting a device including the clot activation material into the surface-modified cannula. Conversely, in other embodiments, obstructing the one or more surface features involves inserting the cannula into a device including the clot activation material.
[0035] Turning to
[0036] As illustrated, the ports 802 may be generally circular in shape. In other embodiments, at least a portion of the ports 802 may be elliptical, tear drop shaped, or elongated slots. The ports 802, in some examples, may be arranged annularly, axially, or serpentine about the surface. In some embodiments, the ports form an open spring similar to a coil about the surface of the hollow shaft. For example, a portion of the hollow shaft including the ports 802 may be formed as a spring segment having gaps between the coils. The flexible spring segment may be particularly useful in embodiments configured as a guidewire style cannula. Alternatively, materials having spring like properties may be configured axially, and compressed annularly to advance through a cannula. Upon exiting the distal end of a cannula, they expand radially, so when partially withdrawn from a blood vessel, they tent open the vessel wound thus allowing blood to eject into the tissue tract.
[0037] Turning to
[0038] As illustrated the channels 812 are generally identical in length and arranged in parallel on the shaft 814. The channels 812, for example, may be evenly disposed around a circumference of the shaft 814. In other embodiments, one or more channels may curve around the circumference of the shaft 814 and/or follow a zig-zag or sinusoidal pattern. In some embodiments, the channels form a flexible bellows about the surface of the hollow shaft. For example, a portion of the hollow shaft including the channels 812 may be formed as an annular or spiral bellows segment having ridges and depressions.
[0039] In use, as blood escapes the wound site in the vessel via the surface-modified cannula, sheath, guidewire, needle, and/or dilator, a user maintains the surface-modified cannula in place for a predetermined period of time, such as between one second and three minutes. The predetermined period of time, in some preferred embodiments, may include at least 10 seconds, 15 seconds, or about 30 seconds, although time will vary depending upon the diameter of the cannula as well as the design and/or distribution of the surface features. Instead of or in addition to the predetermined period of time, in some embodiments, the practitioner watches for a visual indication of presence of blood in the tissue tract, such as swelling at the surface of the skin and/or blood escaping from the skin level.
[0040] After maintaining the cannula in place until the predetermined period of time and/or until noting presence of blood in the tissue tract, the user may proceed with completing an otherwise normal Seldinger access. For example, the practitioner may replace the cannula with another medical device such as a sheath, needle, and/or probe.
[0041] Meanwhile the blood redirected to the region around the wound site and in the tissue tract along the access path by the surface-modified cannula will clot around vessel and along the tissue tract for the duration of the medical procedure, thus sealing off internal bleeding pathways. While such a medical procedure may typically conclude with a ten-minute manual compression period using a topical bandage, due to the sealing process occurring during the medical procedure, standard manual compression may not be required. Further, no closure device may be required, and there may be no delay in patient ambulation.
[0042] Some embodiments may also include kits including or consisting of any devices or combinations of devices described herein or though related references, and typically instructions for their use. Examples of devices suitable for kits include a Seldinger needle, guidewire, a dilator, a sheath, a guidewire, a catheter, a cannula, a surface-modified cannula, a blood dispensing tool, a syringe, and/or a pressure gauge. A comprehensive kit may preferably include components required to perform intravascular access such as through Seldinger technique, components useful in forming a failsafe barrier to bleeding, components useful in performing a wound closure, and instructions for use. The instructions for use, for example, may instruct a practitioner to perform steps as discussed in relation to various methods and apparatus described herein. As illustrative example, instructions may direct how a guidewire style cannula should extend through a needle into the vessel and the encasing needle cannula then removed as in traditional Seldinger technique, but upon removal of the needle from the patient, there is pause until evidence of blood flow though the tissue tract exiting at the skin surface, before advancing a traditional Seldinger dilator-sheath assembly over the guidewire into the vessel. Having labels or having instructions for use may be separate or in any combination with a kit and typically provided by a manufacturer, a seller, or a distributor of any form of kit, and done so in any manner allowed by a governing agency, such as the United States Food and Drug Administration. Any and all kit examples above may be recombined, added to, or deleted from, as may be the preference.
[0043] All patents, patent publications, and peer-reviewed publications (i.e., “references”) cited as part of the present patent application are expressly incorporated by reference to the same extent as if each individual reference were specifically and individually indicated as being incorporated by reference. In case of conflict between the present disclosure and the incorporated references, the present disclosure controls.
[0044] It is understood that the invention is not confined to the particular construction and arrangement of parts herein illustrated and described, but embraces such modified forms thereof as come within the scope of the claims.